Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
SOLANA BEACH, Calif., May 01, 2017 -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the first quarter ended March 31, 2017 on Monday, May 15, 2017, after the market closes.
Evoke will hold a conference call on Monday, May 15, 2017 at 4:30 pm ET to discuss the results. Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com.
After the live webcast, the event will be archived on Evoke's website for one year. In addition, a telephonic replay of the call will be available until May 22, 2017. The replay can be accessed by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) with confirmation code 13660963.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing Gimoti, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. Gimoti is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through nasal administration. Visit www.EvokePharma.com for more information.
Investor Contact: The Ruth Group Tram Bui Tel: 646-536-7035 [email protected]
